Freeline to present data on AAV-based gene therapies for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium 2020

London, 5 February 2020 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces it will present data on its gene therapy programmes for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™ in Orlando, Florida, 10–13 February 2020. Freeline data has been selected for two oral presentations and associated posters at the conference.

 

Oral presentations during the session for Gene Therapy Translational Research:

 

Title: First-in-human study of a liver-directed AAV gene therapy (FLT190) in Fabry Disease

Presenter: Derralynn A Hughes, Royal Free Hospital & University College London, UK

Date and Time: Wednesday 12th February 2020, 8.30 AM

 

Title: One-off liver directed AAV gene therapy achieves long term uptake of acid beta-glucocerebrosidase by macrophages of affected tissues in Gaucher disease

Presenter: Carlos Miranda, Freeline, Stevenage, UK

Date and Time: Wednesday 12th February, 11.15 AM.

 

The data will also be presented as posters on Tuesday 11th February, from 4:30-6:30 PM:

 

First-in-human study of a liver-directed AAV gene therapy (FLT190) in Fabry Disease

Poster Number: 179

 

One-off liver directed AAV gene therapy achieves long term uptake of acid beta-glucocerebrosidase by macrophages of affected tissues in Gaucher disease

Poster Number: 274

- Ends -

 

Further information

JW Communications

Julia Wilson

+44 (0) 7818 430877

juliawilsonuk@gmail.com

 

About Freeline

Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver. Our vision is to create better lives for people suffering from chronic systemic diseases using the potential of gene therapy as a one-time curative treatment. Freeline is headquartered in the UK and has operations in Germany and the US.

To read more Press Release articles, click here.